Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.,Antiviral Therapy

当前位置： X-MOL 学术 › Antivir. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.
Antiviral Therapy ( IF 1.2 ) Pub Date : 2017-4-20 , DOI: 10.3851/imp3168
John Lubel _{1,

2} , Simone Strasser ₃ , Katherine A Stuart ₄ , Gregory Dore ₅ , Alexander Thompson _{6,

7} , Stephen Pianko ₈ , Steven Bollipo ₉ , Joanne L Mitchell ₁₀ , Vincenzo Fragomeli ₁₁ , Tracey Jones ₉ , Sarah Chivers ₂ , Paul Gow ₁₂ , David Iser ₆ , Miriam Levy ₁₃ , Edmund Tse ₁₄ , Alessia Gazzola ₁₀ , Wendy Cheng ₁₅ , Saroj Nazareth ₁₅ , Sam Galhenage ₁₆ , Amanda Wade ₁₇ , Martin Weltman ₁₁ , Alan Wigg ₁₈ , Gerry MacQuillan _{19,

20} , Joe Sasadeusz ₂₁ , Jacob George _{22,

23} , Amany Zekry ₂₄ , Stuart K Roberts ₁₀ ,

Affiliation

Department of Gastroenterology, Eastern Health, Melbourne, VIC, Australia.
Eastern Health Clinical School, Monash University, Melbourne, VIC, Australia.
AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
HIV, Immunology, Infectious Diseases Department, St Vincent's Hospital, Sydney, NSW, Australia.
Department of Gastroenterology, St Vincent's Hospital, Melbourne, VIC, Australia.
University of Melbourne, Melbourne, VIC, Australia.
Department of Gastroenterology, Monash Health, Melbourne, VIC, Australia.
Department of Gastroenterology, John Hunter Hospital, Newcastle, NSW, Australia.
Department of Gastroenterology, Alfred Health, Melbourne, VIC, Australia.
Department of Gastroenterology, Nepean Hospital, Sydney, NSW, Australia.
Victorian Liver Transplant Unit, Austin Health, Melbourne, VIC, Australia.
Department of Gastroenterology, Liverpool Hospital, Sydney, NSW, Australia.
Department of Gastroenterology, Royal Adelaide Hospital, Adelaide, SA, Australia.
Department of Gastroenterology, Royal Perth Hospital, Perth, WA, Australia.
Department of Gastroenterology, Fiona Stanley Hospital, Perth, WA, Australia.
Infectious Diseases, Barwon Health, Geelong, VIC, Australia.
Hepatology and Liver Transplant Medicine Unit, Flinders Medical Centre, Adelaide, SA, Australia.
WA Liver Transplantation Service, Department of Hepatology, Sir Charles Gairdner Hospital, Perth, WA, Australia.
School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia.
VIDS and Peter Doherty Institute, Royal Melbourne Hospital, Melbourne, VIC, Australia.
Storr Liver Centre, Westmead Institute for Medical Research, Sydney, NSW, Australia.
University of Sydney, Sydney, NSW, Australia.
Department of Gastroenterology and Hepatology, St George Hospital, Sydney, NSW, Australia.

Limited data exist on the outcomes of ritonavir-boosted paritaprevir with ombitasvir and dasabuvir (PrOD) ± ribavirin in a real-world setting. The aim of this study was to compare the efficacy and safety of PrOD-based therapy in hepatitis C genotype 1 patients with and without cirrhosis, and to explore pre-treatment factors predictive of sustained viral response (SVR) and serious adverse events (SAEs) on treatment.

中文翻译：

利托那韦增强的paritaprevir，ombitasvir，dasabuvir±利巴韦林对丙型肝炎基因型1的真实疗效和安全性-REV1TAL研究的最终结果。

在真实环境中，使用利托那韦增强的帕利他普韦与ombitasvir和dasabuvir（PrOD）±利巴韦林的疗效相关的数据有限。这项研究的目的是比较基于PrOD的疗法在有和没有肝硬化的C型基因型1型肝炎患者中的疗效和安全性，并探讨预测持续病毒应答（SVR）和严重不良事件（SAE）的治疗前因素。在治疗上。

更新日期：2020-08-21

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>